No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression

J Neuroimmunol. 2012 Feb 29;243(1-2):69-72. doi: 10.1016/j.jneuroim.2011.12.006. Epub 2012 Jan 12.

Abstract

Inflammation may contribute to the pathogenesis of depression and antidepressants are hypothesised to have an anti-inflammatory effect. In this randomised double-blinded trial we investigated the cytokine levels in supernatants of stimulated whole blood samples from first degree relatives to patients with depression randomised to a single daily dose of either 10mg escitalopram or placebo for four weeks. No significant differences were found in any of the cytokine levels between the participants treated with escitalopram (n=21) or placebo (n=23). Our data does thus not support the hypothesis of a global anti-inflammatory effect of escitalopram on cytokines in healthy subjects.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Age Factors
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Blood Cells / drug effects
  • Blood Cells / metabolism
  • Citalopram / therapeutic use*
  • Cytokines / blood
  • Depression / drug therapy*
  • Depression / genetics
  • Depression / pathology
  • Double-Blind Method
  • Family Health*
  • Follow-Up Studies
  • Humans
  • Lipopolysaccharides / pharmacology
  • Middle Aged
  • Polyhydroxyalkanoates / pharmacology
  • Retrospective Studies
  • Young Adult

Substances

  • Antidepressive Agents, Second-Generation
  • Cytokines
  • Lipopolysaccharides
  • Polyhydroxyalkanoates
  • Citalopram